Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy

Lutz Gieselmann, Andrew T. DeLaitsch, Malena Rohde, Henning Gruell, Christoph Kreer, Meryem S. Ercanoglu, Harry B. Gristick, Philipp Schommers, Elvin Ahmadov, Caelan E. Radford, Andrea Mazzolini, Lily Zhang, Anthony P. West, Johanna Worczinski, Anna Momot, Maren L. Reichwein, Jacqueline Knüfer, Ricarda Stumpf, Nonhlanhla N. Mkhize, Haajira Kaldine, Sinethemba Bhebhe, Sharvari Deshpande, Franco Giovannoni, Erin Stefanutti, Fabio Benigni, Colin Havenar‐Daughton, Davide Corti, Arne Kroidl, Anurag Adhikari, Aubin Nanfack, Georgia Ambada, Ralf Duerr, Wiston William, Nyanda Elias Ntinginya, Timo Wolf, Christof Geldmacher, Michael Hoelscher, Clara Lehmann, Penny L. Moore, Thierry Mora, Aleksandra M. Walczak, Peter B. Gilbert, Nicole A. Doria‐Rose, Yunda Huang, Jesse D. Bloom, Michael S. Seaman, Pamela J. Björkman, Florian KleinbioRxiv 2025 · DOI

TL;DR

This paper identifies a new, highly potent, and broadly neutralizing antibody (bNAb) called 04_A06 from elite HIV-1 neutralizers. This bNAb shows remarkable efficacy in preclinical models and against diverse HIV-1 strains, including those resistant to other bNAbs, making it a promising candidate for HIV-1 prevention and therapy.

What Problem Does This Paper Address?

HIV-1's rapid evolution and sequence diversity pose a major challenge for developing effective treatments and preventative measures using neutralizing antibodies. While broadly neutralizing antibodies (bNAbs) have shown promise, their clinical application is hampered by the emergence of viral escape variants. This study aims to address this by identifying novel bNAbs with superior potency and breadth that can overcome these escape mechanisms.

Methods

The researchers employed a multi-pronged approach:

  • Single B Cell Profiling: They analyzed B cells from 32 HIV-1 elite neutralizers to identify potential bNAb candidates. This involved isolating and expressing 831 monoclonal antibodies (mAbs).
  • High-Throughput Screening: These mAbs were tested for neutralizing activity against a panel of HIV-1 pseudoviruses.
  • Structural Analysis: The structure of the most promising antibody, 04_A06, was determined using cryo-EM to understand its binding mechanism.
  • In Vivo Studies: The efficacy of 04_A06 was evaluated in humanized mice infected with HIV-1.
  • In Silico Modeling: The potential for 04_A06 in HIV-1 prevention was modeled using pharmacokinetic data.
  • Deep Mutational Scanning (DMS): This technique was used to comprehensively map how mutations in the HIV-1 Env protein affect neutralization by 04_A06 and other bNAbs.

Datasets

  • HIV-1 Pseudovirus Panels: The study utilized various panels of HIV-1 pseudoviruses, including a 12-strain global panel, multiclade panels (119 and 208 strains), a clade C panel, and panels derived from the Antibody Mediated Prevention (AMP) trials.
  • HIV-1 Env Escape Mutation Libraries: A library of known HIV-1 Env escape mutations and a lentivirus deep mutational scanning platform were used to assess resistance patterns.
  • Humanized Mouse Model Data: Viral load data from humanized mice infected with HIV-1 YU2 were collected.
  • AMP Trial Data: Pseudoviruses from the AMP trials were used to assess the potential of 04_A06 for prevention.

Key Insights and Ideas

  • An 11-amino acid insertion in FWRH1 is key: This insertion in 04_A06 is crucial for its broad activity, enabling it to make unique contacts with conserved residues on the HIV-1 Env trimer and overcome escape mechanisms.
  • 04_A06 has a distinct binding mode: Unlike other VRC01-class bNAbs, 04_A06 does not bind to the RSC3 protein, suggesting a different epitope recognition.
  • Elite neutralizers are a rich source of potent bNAbs: The study highlights the value of profiling elite neutralizers to discover antibodies with exceptional breadth and potency.
  • Viral escape is complex and context-dependent: DMS revealed that while some mutations escape other bNAbs, 04_A06 shows remarkable resistance, suggesting a more robust interaction.

Key Results

  • Identification of 04_A06: A new CD4bs bNAb, 04_A06, was identified with remarkable breadth (98.5% against 332 strains) and potency (GeoMean IC50 = 0.059 µg/ml).
  • Resistance to Escape: 04_A06 was not susceptible to classic viral CD4bs escape variants and showed minimal escape in DMS studies.
  • In Vivo Efficacy: 04_A06 achieved complete and sustained suppression of viremia in HIV-1 YU2-infected humanized mice, outperforming other bNAbs. It also overcame VRC01-class resistant viruses.
  • Prevention Potential: In silico modeling predicted a prevention efficacy of >93% for an extended half-life variant of 04_A06.
  • Structural Basis: Cryo-EM revealed that an 11-amino acid insertion in 04_A06's heavy chain facilitates inter-protomer contacts, contributing to its broad activity.

Limitations and Future Work

  • In Vivo Model Limitations: The in vivo studies were conducted using a single HIV-1 strain (YU2), and future studies should incorporate a broader panel of viral strains or heterogeneous viral swarms to better recapitulate viral diversity.
  • DMS Context: The DMS analyses were conducted in the context of a single HIV-1 pseudovirus strain (HIV-1 BF520), and findings may not be generalizable to other strains.
  • PK Assumptions: In silico prevention efficacy predictions rely on assumptions about pharmacokinetic behavior that may not perfectly reflect human pharmacokinetics.
  • Future Directions: The authors suggest further studies to explore the potential of 04_A06 for clinical application in both treatment and prevention strategies, particularly in vulnerable populations like children. They also highlight the need for continued efforts to identify bNAbs with enhanced potency, breadth, and restricted escape pathways.

Summary updated

Abstract

Administration of HIV-1 neutralizing antibodies can suppress viremia and prevent infection <i>in vivo</i>. However, clinical use is challenged by broad envelope sequence diversity and rapid emergence of viral escape<sup>1-9</sup>. Here, we performed single B cell profiling of 32 top HIV-1 elite neutralizers to identify broadly neutralizing antibodies (bNAbs) with highest potency and breadth for clinical application. From 831 expressed monoclonal antibodies, we identified 04_A06, a new V<sub>H</sub>1-2-encoded CD4 binding site bNAb with remarkable breadth and potency against extended multiclade pseudovirus panels (GeoMean IC<sub>50</sub> = 0.059 μg/ml, breadth = 98.5%, 332 virus strains). Moreover, 04_A06 was not susceptible to classic viral CD4bs escape variants and maintained full viral suppression in HIV-1-infected humanized mice. Structural analyses revealed that antiviral activity is mediated by an unusually long 11-amino acid heavy chain insertion. This insertion facilitates inter-protomer contacts and interactions with highly conserved residues on the adjacent gp120 protomer. Finally, 04_A06 demonstrated high activity against contemporaneously circulating viruses from the Antibody Mediated Prevention (AMP) trials (GeoMean IC<sub>50</sub> = 0.082 μg/ml, breadth = 98.4%, 191 virus strains) and <i>in silico</i> modeling for 04_A06LS predicted HIV-1 prevention efficacy of >93%. Thus, 04_A06 will provide unique opportunities for effective treatment and prevention strategies of HIV-1 infection.
BibTeX
@misc{gieselmann2025profiling,
  author = {Lutz Gieselmann and Andrew T. DeLaitsch and Malena Rohde and Henning Gruell and Christoph Kreer and Meryem S. Ercanoglu and Harry B. Gristick and Philipp Schommers and Elvin Ahmadov and Caelan E. Radford and Andrea Mazzolini and Lily Zhang and Anthony P. West and Johanna Worczinski and Anna Momot and Maren L. Reichwein and Jacqueline Knüfer and Ricarda Stumpf and Nonhlanhla N. Mkhize and Haajira Kaldine and Sinethemba Bhebhe and Sharvari Deshpande and Franco Giovannoni and Erin Stefanutti and Fabio Benigni and Colin Havenar‐Daughton and Davide Corti and Arne Kroidl and Anurag Adhikari and Aubin Nanfack and Georgia Ambada and Ralf Duerr and Davide Corti and Wiston William and Nyanda Elias Ntinginya and Timo Wolf and Christof Geldmacher and Michael Hoelscher and Clara Lehmann and Penny L. Moore and Thierry Mora and Aleksandra M. Walczak and Peter B. Gilbert and Nicole A. Doria‐Rose and Yunda Huang and Jesse D. Bloom and Michael S. Seaman and Pamela J. Björkman and Florian Klein},
  title = {{Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy}},
  year = {2025},
  doi = {10.1101/2025.08.27.672638},
  howpublished = {bioRxiv},
}
Figure